COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer (ANICCA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03981146
Recruitment Status : Recruiting
First Posted : June 10, 2019
Last Update Posted : November 6, 2020
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
University of Birmingham

Tracking Information
First Submitted Date  ICMJE May 9, 2019
First Posted Date  ICMJE June 10, 2019
Last Update Posted Date November 6, 2020
Actual Study Start Date  ICMJE August 28, 2019
Estimated Primary Completion Date February 28, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 7, 2019)
Durable Clinical Benefit [ Time Frame: Beginning of trial treatment to free of disease progression (104 weeks maximum) ]
patient will be defined as experiencing DCB if they remain free of disease progression at their third trial specific CT scan since treatment start date (i.e. at approximately 27 weeks) or at any CT scan after 27 weeks that shows the patient remains free of disease progression
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 7, 2019)
  • Objective response [ Time Frame: trial treatment until disease progression (104 weeks maximum) ]
    Objective response is the occurrence of CR or PR as the best overall response
  • Best Percentage Change in Sum of Target Lesions [ Time Frame: Trial Treatment to disease progression (104 weeks maximum) ]
    At each evaluation, the longest diameters of all selected target lesions will be measured and summed and the percentage change from the baseline measurement will be calculated. The best percentage change is the one that reflects either the greatest decrease or the least increase over the whole period of assessment.
  • Time to Maximal Response [ Time Frame: Occurrence of CR or PR during the trial (104 weeks maximum) ]
    This is defined as the time from commencement of trial treatment to the date of CT scan that first records the best objective response as per RECIST version 1.1.
  • Progression Free Survival Time [ Time Frame: time from commencement of trial treatment to the date of CT scan when progressive disease first recorded (104 weeks maximum) ]
    This is defined as the time from commencement of trial treatment to the date of CT scan when progressive disease first recorded or date of death without previously recorded progression.first records the best objective response as per RECIST version 1.1.
  • Overall Survival Time [ Time Frame: Trial Treatment to date of death. ]
    This is defined as the time from commencement of trial treatment to the date of death.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
Official Title  ICMJE A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
Brief Summary An open-label, single-arm, phase II, multicentre clinical trial to determine the rate of durable clinical benefit of nivolumab in patients with class II expressing microsatellite stable colorectal cancer.
Detailed Description

Immuno-oncology is transforming the care of certain patients with cancer. Not all patients respond to these therapies however, and in some common cancers checkpoint blockade has failed to make any real impact. In 2014 there were over 41,000 new cases of colorectal cancer (CRC) in the UK and nearly 16,000 deaths from the disease, making it the second commonest cause of cancer death (Cancer Research UK Cancer Statistics Key Facts). 15% of patients with CRC develop it as a result of deficient mismatch repair (microsatellite instability - MSI): this cohort of patients respond well to PD-1/PD-L1 blockade as these tumours harbour a very high number of mutations thus increasing the likelihood of the presence of immunogenic neo-epitopes which elicit an immune response1. The majority of CRC patients, particularly those with metastatic disease (around 95%), do not display this hyper-mutator phenotype (microsatellite stable (MSS) CRC) and in these patients the results of PD-1/PD-L1 blockade have been disappointing.

In summary, MSS CRC patients with a class II expression appear to represent immunologically a group of MSI-like MSS patients that may respond to usefully to the immunotherapy agent nivolumab as a single agent and thus a trial of nivolumab in patients with class II expression of their cancer cells appears to be highly justified.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Colorectal Cancer
Intervention  ICMJE Drug: Nivolumab
60 Minute IV Infusion
Study Arms  ICMJE Experimental: Nivolumab
Patients will receive 480mg of Nivolumab on a four weekly cycle for a maximum of two years.
Intervention: Drug: Nivolumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: June 7, 2019)
36
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE February 28, 2023
Estimated Primary Completion Date February 28, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histologically confirmed locally advanced or metastatic MSS CRC with class II expression (greater than 1% cancer cell positivity for class II expression on immunohistochemistry).
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (APPENDIX 1)
  • Age ≥ 18 years
  • Patients must have completed all standard of care therapy that the treating oncologist deems appropriate. Trial treatment as first line therapy is permitted if the patient has declined standard of care therapy.
  • CT scan of chest, abdomen, pelvis within 28 days of registration demonstrating unidimensionally measurable disease as per RECIST version 1.1 (APPENDIX 3).
  • Demonstrate adequate haematological function:

    • Platelet count ≥100 x 109 /L
    • Neutrophils ≥1.5 x 109/L
    • Haemoglobin ≥ 90 g/L
  • Demonstrate adequate hepatic function:

    • Serum bilirubin ≤1.5 x upper limit of normal (ULN)
    • Serum AST or ALT ≤2.5 x ULN or <5 x ULN in the presence of liver metastases
  • Demonstrate adequate renal function

    o Creatinine clearance <1.5 times ULN and >30ml/min (as per institutional standard).

  • Provision of signed and dated, written informed consent prior to any trial specific procedures, sampling and analyses.
  • Negative pregnancy test (female patients of reproductive potential). (Serum Test must be negative)
  • Patients must agree to the use of contraception as detailed in section 7.8

Exclusion Criteria:

  • Previous treatment with PD1/PDL1 inhibitors.

    • Untreated symptomatic brain or leptomeningeal metastatic disease.
    • Medical or psychiatric conditions compromising informed consent.
    • Any medical condition which, in the opinion of the Investigator, would compromise the ability of the patient to participate in the trial or which would jeopardise compliance with the protocol.
    • Administration of chemotherapy, radioactive or biological cancer therapy within 4 weeks prior to the first dose of trial therapy Patient has not recovered to CTCAE grade 1 or better from the Adverse Event (AE) due to cancer therapeutics administered more than 4 weeks earlier.
    • Active autoimmune disease that has required systemic treatment in past 2 years (i.e.

with use of disease modifying agents, corticosteroids or immunosuppressive drugs).

Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.

  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Patient has risk factors for bowel obstruction or bowel perforation (examples include but not limited to a history of acute diverticulitis, intra-abdominal abscess and abdominal carcinomatosis).
  • Patient has a known history of other malignancy, unless the patient has undergone potentially curative therapy with no evidence of that disease for 3 years.
  • Has a history of non-infectious pneumonitis requiring steroids or has active pneumonitis.
  • Female patients that are either pregnant or breast feeding.
  • Male and female patients (of childbearing age) not willing to use adequate contraception.
  • Patient previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody.
  • Patient is positive for Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), active Hepatitis B (HBsAg reactive) or Hepatitis C (HCV RNA (qualitative) is detected); patients with negative Hepatitis C antibody testing may not need RNA testing.
  • Known history of tuberculosis.
  • Patient has an active infection requiring therapy.
  • Has received a live vaccine within 30 days prior to the first dose of trial treatment.
  • Patient is, at the time of signing informed consent, a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: ANICCA Trial Office 0121 414 6754 anicca-classii@trials.bham.ac.uk
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03981146
Other Study ID Numbers  ICMJE RG_17-215
2018-000318-39 ( EudraCT Number )
40245896 ( Registry Identifier: ISRCTN )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party University of Birmingham
Study Sponsor  ICMJE University of Birmingham
Collaborators  ICMJE Bristol-Myers Squibb
Investigators  ICMJE
Principal Investigator: Gary Middleton, MB,BS,FRCP University of Birmingham
PRS Account University of Birmingham
Verification Date November 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP